Related Experiment Videos
Third look surgery and beyond for appendiceal malignancy with peritoneal dissemination
Faheez Mohamed1, David Chang, Paul H Sugarbaker
1The Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA.
Journal of Surgical Oncology
|May 2, 2003
Summary
Complete cytoreduction improves survival in patients undergoing multiple reoperations for appendiceal malignancy. However, cancer cure remains rare after four or more interventions, suggesting tumor biology becomes dominant.
Area of Science:
- Surgical oncology
- Gastrointestinal oncology
Background:
- Recurrent peritoneal dissemination from appendiceal malignancy presents challenges for repeat surgical interventions.
- Established criteria for third, fourth, and subsequent reoperations are lacking.
Purpose of the Study:
- To evaluate survival outcomes and identify predictors of success in patients undergoing multiple reoperations for appendiceal malignancy.
- To establish selection criteria for subsequent reoperative surgeries.
Main Methods:
- Analysis of a prospective database of 501 patients with appendiceal epithelial peritoneal surface malignancy treated with cytoreductive surgery and intraperitoneal chemotherapy.
- Focus on 45 patients (8.9%) who underwent three or more operative interventions.
- Statistical analysis of clinical features and survival rates.
Main Results:
- Overall 5-year survival for patients with 3+ reoperations was 70%.
- Survival rates increased with the number of interventions up to five or more (100% 5-year survival).
- Complete cytoreduction for second and third interventions correlated with improved 5-year survival; tumor biology became more influential after four interventions.
Conclusions:
- Complete cytoreduction is a significant factor for prolonged survival in patients with recurrent appendiceal malignancy undergoing multiple reoperations.
- After four or more interventions, tumor biology appears to be the predominant factor influencing outcomes.
- While multiple reoperations can lead to prolonged survival, cancer cure is infrequent.